MENLO PARK, Calif. — July 10, 2007— ForteBio, Inc., developer of label-free systems for real-time detection and analysis of molecular interactions, announced today the appointment of Katherine J. Flagg as Vice President of Sales, reporting to Winnie H. Wan, Ph.D., President and Chief Executive Officer. In this new position at ForteBio, Ms. Flagg will lead the company's North American sales and field application scientist teams. She is also responsible for ForteBio product distribution in Europe, Asia and other parts of the world. Ms. Flagg joined ForteBio from Rapid Micro Biosystems, where she was Vice President, Business Development.
“We are so pleased to have someone with Katherine's expertise joining ForteBio at this time,” stated Winnie H. Wan, Ph.D., President and Chief Executive Officer. “Her familiarity with the international biotechnology and pharmaceutical industry is particularly helpful given ForteBio's goal of penetrating the life science markets in both the U.S. and Europe with our Octet System for label-free, real-time analysis of molecular interactions.” Ms. Flagg has nearly 20 years experience in the life sciences industry, including 9 years at BioVeris/IGEN Corporation (recently acquired by Roche), where she held a number of positions with increasing sales and management responsibilities. As Director of Sales of Life Sciences and BioSecurity, she successfully led a global account strategy to increase sales to major pharmaceutical companies in both Europe and the U.S. Previously, at Pharmacia Biotech (now GE HealthSciences), Ms. Flagg represented the company's automated DNA sequencing and synthesis products.
Ms. Flagg received her BS in Nutrition from Douglass College at Rutgers University. She is a member of the Laboratory Robotics Interest Group and the Parenteral Drug Association.
About ForteBio, Inc.
ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of therapeutics. These systems enable real-time analysis of biomolecular interactions providing information on affinity, kinetics and concentration. Most importantly, ForteBio's analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California with a wholly owned subsidiary in Shanghai, China. For more information, please visit www.fortebio.com.
Contact Information :
Winnie H. Wan, Ph.D.
President & Chief Executive
650-322-1360 ext 6888